ECSP15042897A - Formulaciones orales de deferasirox - Google Patents
Formulaciones orales de deferasiroxInfo
- Publication number
- ECSP15042897A ECSP15042897A ECIEPI201542897A ECPI201542897A ECSP15042897A EC SP15042897 A ECSP15042897 A EC SP15042897A EC IEPI201542897 A ECIEPI201542897 A EC IEPI201542897A EC PI201542897 A ECPI201542897 A EC PI201542897A EC SP15042897 A ECSP15042897 A EC SP15042897A
- Authority
- EC
- Ecuador
- Prior art keywords
- deferasirox
- tablet
- exposure
- present
- tablets
- Prior art date
Links
- 229960001489 deferasirox Drugs 0.000 title abstract 4
- BOFQWVMAQOTZIW-UHFFFAOYSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N1C(C=2C(=CC=CC=2)O)=NC(C=2C(=CC=CC=2)O)=N1 BOFQWVMAQOTZIW-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000003826 tablet Substances 0.000 abstract 6
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 abstract 3
- 238000004090 dissolution Methods 0.000 abstract 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000002184 metal Substances 0.000 abstract 2
- 229910052751 metal Inorganic materials 0.000 abstract 2
- 230000007935 neutral effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000007919 dispersible tablet Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229940024583 exjade Drugs 0.000 abstract 1
- 230000009246 food effect Effects 0.000 abstract 1
- 235000021471 food effect Nutrition 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361774893P | 2013-03-08 | 2013-03-08 | |
| US201361824435P | 2013-05-17 | 2013-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP15042897A true ECSP15042897A (es) | 2019-03-29 |
Family
ID=50288212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201542897A ECSP15042897A (es) | 2013-03-08 | 2015-10-08 | Formulaciones orales de deferasirox |
Country Status (41)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2708955T5 (es) | 2013-03-08 | 2023-11-10 | Novartis Ag | Formulaciones orales de deferasirox |
| US9866684B2 (en) * | 2015-02-16 | 2018-01-09 | Microsoft Technology Licensing, Llc | Process for real-time data exchange between users on a phone call |
| WO2016167729A1 (en) * | 2015-04-16 | 2016-10-20 | Öğün Yusuf Toktamiş | Dispersible tablets comprising deferasirox |
| WO2016205658A1 (en) | 2015-06-17 | 2016-12-22 | Dispersol Technologies, Llc | Improved formulations of deferasirox and methods of making the same |
| EP3429562A1 (en) | 2016-03-17 | 2019-01-23 | Lupin Limited | Compositions of deferasirox |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| CA3029543C (en) * | 2016-07-05 | 2021-11-23 | Jubilant Generics Limited | Immediate release pharmaceutical composition of iron chelating agents |
| EP3518904A1 (en) | 2016-09-30 | 2019-08-07 | Synthon B.V. | Pharmaceutical composition comprising deferasirox |
| CZ2017255A3 (cs) | 2017-05-04 | 2018-11-14 | Zentiva, K.S. | Filmem potažené tablety Deferasiroxu |
| TR201707764A2 (tr) * | 2017-05-29 | 2018-12-21 | Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi | Deferasiroksun bölünebilir tablet formları. |
| WO2019108156A1 (en) * | 2017-11-28 | 2019-06-06 | Biofarma Ilac Sanayi Ve Ticaret A.S. | A scored tablet formulation comprising deferasirox in a film tablet form |
| KR20200113116A (ko) | 2019-03-22 | 2020-10-06 | 주식회사 한국팜비오 | 데페라시록스를 포함하는 필름코팅정제 |
| EP3854385A1 (en) * | 2020-01-27 | 2021-07-28 | ROS Therapeutics ApS | Methotrexate dosage form |
| EP4052698A1 (en) * | 2021-03-05 | 2022-09-07 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Film coated tablet comprising deferasirox |
| CN115154428B (zh) * | 2022-09-06 | 2023-01-10 | 上海奥科达医药科技股份有限公司 | 一种地拉罗司药物组合物及其制备方法 |
| WO2025242589A1 (en) | 2024-05-21 | 2025-11-27 | Chiesi Farmaceutici S.P.A. | Pharmaceutical dosage forms for deferiprone and deferasirox combined therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY129541A (en) * | 1996-06-25 | 2007-04-30 | Novartis Ag | Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| GB0223978D0 (en) | 2002-10-15 | 2002-11-20 | Novartis Ag | Organic compound |
| KR20070022243A (ko) * | 2004-04-08 | 2007-02-26 | 노파르티스 아게 | 데페라시록스 분산성 정제 |
| GB0408078D0 (en) * | 2004-04-08 | 2004-05-12 | Novartis Ag | Organic compounds |
| BRPI0617715A2 (pt) * | 2005-10-19 | 2011-08-02 | Novartis Ag | comprimidos dispersìveis compreendendo deferasirox |
| EP2062572A1 (en) * | 2007-11-19 | 2009-05-27 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions |
| WO2009106824A2 (en) | 2008-02-25 | 2009-09-03 | Cipla Limited | Pharmaceutical formulations |
| WO2009130604A2 (en) | 2008-04-21 | 2009-10-29 | Actavis Group Ptc Ehf | Solid state forms of deferasirox salts and process for the preparation thereof |
| WO2010035282A1 (en) | 2008-09-24 | 2010-04-01 | Matrix Laboratories Limited | Pharmaceutical compositions comprising deferasirox |
| WO2010143006A1 (en) * | 2009-06-10 | 2010-12-16 | Carlo Ghisalberti | Orally bioavailable iron chelators in the treatment of an inflammatory bowel disease |
| WO2012003987A1 (en) * | 2010-07-08 | 2012-01-12 | Ratiopharm Gmbh | Oral dosage form of deferasirox |
| BR112013007276A2 (pt) | 2010-10-01 | 2016-06-14 | Cipla Ltd | composição farmacêutica, processo para preparar uma composição farmacêutica, uso da coposição farmacêutica e método para tratar sobrecarga crônica de ferro |
| ES2708955T5 (es) | 2013-03-08 | 2023-11-10 | Novartis Ag | Formulaciones orales de deferasirox |
| EP3429562A1 (en) | 2016-03-17 | 2019-01-23 | Lupin Limited | Compositions of deferasirox |
-
2014
- 2014-03-06 ES ES14710654T patent/ES2708955T5/es active Active
- 2014-03-06 KR KR1020157027470A patent/KR101925671B1/ko active Active
- 2014-03-06 JP JP2015560837A patent/JP6434429B2/ja active Active
- 2014-03-06 HR HRP20190173TT patent/HRP20190173T1/hr unknown
- 2014-03-06 CA CA2890465A patent/CA2890465A1/en not_active Abandoned
- 2014-03-06 EP EP16188627.0A patent/EP3124018B2/en active Active
- 2014-03-06 JO JOP/2014/0075A patent/JO3570B1/ar active
- 2014-03-06 CN CN201480012815.XA patent/CN105025886B/zh active Active
- 2014-03-06 PL PL16188627T patent/PL3124018T3/pl unknown
- 2014-03-06 AP AP2015008668A patent/AP2015008668A0/xx unknown
- 2014-03-06 SI SI201431064T patent/SI2964202T1/sl unknown
- 2014-03-06 RS RS20190142A patent/RS58317B1/sr unknown
- 2014-03-06 PT PT14710654T patent/PT2964202T/pt unknown
- 2014-03-06 ES ES16188627T patent/ES2663135T5/es active Active
- 2014-03-06 EA EA201591665A patent/EA031719B1/ru not_active IP Right Cessation
- 2014-03-06 UY UY0001035367A patent/UY35367A/es not_active Application Discontinuation
- 2014-03-06 TW TW107112193A patent/TWI686215B/zh active
- 2014-03-06 SG SG10201807204YA patent/SG10201807204YA/en unknown
- 2014-03-06 SG SG11201506491RA patent/SG11201506491RA/en unknown
- 2014-03-06 MY MYPI2015702695A patent/MY170303A/en unknown
- 2014-03-06 DK DK16188627.0T patent/DK3124018T3/en active
- 2014-03-06 HU HUE16188627A patent/HUE036921T2/hu unknown
- 2014-03-06 LT LTEP14710654.6T patent/LT2964202T/lt unknown
- 2014-03-06 SI SI201430621T patent/SI3124018T1/en unknown
- 2014-03-06 US US14/198,872 patent/US9283209B2/en active Active
- 2014-03-06 ME MEP-2019-30A patent/ME03297B/me unknown
- 2014-03-06 PT PT161886270T patent/PT3124018T/pt unknown
- 2014-03-06 LT LTEP16188627.0T patent/LT3124018T/lt unknown
- 2014-03-06 BR BR112015021254A patent/BR112015021254A2/pt not_active IP Right Cessation
- 2014-03-06 EP EP14710654.6A patent/EP2964202B2/en active Active
- 2014-03-06 PE PE2015001870A patent/PE20151600A1/es unknown
- 2014-03-06 RS RS20180167A patent/RS56890B1/sr unknown
- 2014-03-06 MX MX2015011962A patent/MX361055B/es active IP Right Grant
- 2014-03-06 AU AU2014224198A patent/AU2014224198B2/en active Active
- 2014-03-06 PL PL14710654T patent/PL2964202T3/pl unknown
- 2014-03-06 TW TW103107731A patent/TWI625136B/zh active
- 2014-03-06 HU HUE14710654A patent/HUE041224T2/hu unknown
- 2014-03-06 KR KR1020177010591A patent/KR20170045391A/ko not_active Withdrawn
- 2014-03-06 DK DK14710654.6T patent/DK2964202T3/en active
- 2014-03-06 WO PCT/IB2014/059494 patent/WO2014136079A1/en not_active Ceased
- 2014-03-06 NZ NZ711179A patent/NZ711179A/en unknown
- 2014-03-06 CU CUP2015000110A patent/CU24348B1/xx unknown
-
2015
- 2015-05-12 SA SA515360425A patent/SA515360425B1/ar unknown
- 2015-08-20 ZA ZA2015/06060A patent/ZA201506060B/en unknown
- 2015-08-24 IL IL240797A patent/IL240797B/en unknown
- 2015-09-04 TN TN2015000393A patent/TN2015000393A1/en unknown
- 2015-09-07 CL CL2015002495A patent/CL2015002495A1/es unknown
- 2015-09-07 NI NI201500126A patent/NI201500126A/es unknown
- 2015-09-07 PH PH12015501981A patent/PH12015501981A1/en unknown
- 2015-09-08 DO DO2015000220A patent/DOP2015000220A/es unknown
- 2015-09-08 CR CR20150467A patent/CR20150467A/es unknown
- 2015-10-08 EC ECIEPI201542897A patent/ECSP15042897A/es unknown
-
2016
- 2016-02-05 US US15/017,084 patent/US20160220493A1/en not_active Abandoned
-
2017
- 2017-06-08 AU AU2017203897A patent/AU2017203897B2/en active Active
- 2017-06-16 US US15/625,863 patent/US20170290811A1/en not_active Abandoned
-
2018
- 2018-03-06 HR HRP20180387TT patent/HRP20180387T1/hr unknown
- 2018-03-12 CY CY20181100302T patent/CY1120021T1/el unknown
- 2018-03-23 US US15/934,595 patent/US20180221285A1/en not_active Abandoned
- 2018-05-24 JP JP2018099612A patent/JP6739470B2/ja active Active
-
2019
- 2019-01-31 CY CY20191100143T patent/CY1121315T1/el unknown
-
2020
- 2020-06-08 JP JP2020099402A patent/JP2020180123A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP15042897A (es) | Formulaciones orales de deferasirox | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| UY34974A (es) | Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| JP2015038135A5 (enExample) | ||
| NZ631100A (en) | Soft chewable pharmaceutical products | |
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| IN2015DN03921A (enExample) | ||
| EA201590847A1 (ru) | Новые ингибиторы rock | |
| MX2019001596A (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| EA201691034A1 (ru) | Композиции в твердой форме с замедленным высвобождением для перорального введения | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| HRP20161796T1 (hr) | Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| MX2015006011A (es) | Pastilla medicinal a base de ibuprofeno sodico dihidratado. | |
| UY33468A (es) | Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal | |
| MX370184B (es) | Composición farmacéutica que comprende fingolimod. | |
| UY37413A (es) | Formulaciones de liberación inmediata de oprozomib | |
| JP2017509683A5 (enExample) | ||
| EA201791737A1 (ru) | Стабильные составы триентина | |
| PH12015502560B1 (en) | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease | |
| PH12016502591B1 (en) | Pharmaceutical for treating dizziness having different causes |